Walgreens Boots Alliance, one of the largest pharmacy chains in the United States, is facing a civil complaint filed by the Justice Department in the U.S. District Court for the Northern District of Illinois. The complaint alleges that Walgreens violated the Controlled Substances Act (CSA) by dispensing millions of unlawful prescriptions and violated the False Claims Act (FCA) by seeking reimbursement for these prescriptions from federal health care programs.
According to the Justice Department, Walgreens pharmacists filled prescriptions for controlled substances despite clear “red flags” that the prescriptions were likely invalid or lacked a legitimate medical purpose. These included dangerous and excessive quantities of opioids, early refills, and combinations of drugs known as the “trinity,” consisting of an opioid, a benzodiazepine, and a muscle relaxant. The government alleges that Walgreens’ practices fueled the opioid crisis, with tragic consequences including patient overdoses.
Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division, stated that Walgreens systematically pressured pharmacists to fill prescriptions quickly, depriving them of the time and information necessary to verify the validity of controlled substance prescriptions. The complaint alleges that these actions directly contributed to the ongoing opioid epidemic.
From August 2012 to the present, Walgreens allegedly filled millions of unlawful prescriptions while ignoring warnings from its own pharmacists and internal data. Acting U.S. Attorney Morris Pasqual for the Northern District of Illinois underscored the critical role of the CSA and FCA in protecting communities, stating that the office will continue to work with law enforcement to ensure that opioids are dispensed lawfully and taxpayer funds are used appropriately.
U.S. Attorney Erek L. Barron for the District of Maryland emphasized that pharmacies are essential in preventing the illegal distribution of controlled substances, a responsibility Walgreens failed to meet. Acting U.S. Attorney Carolyn Pokorny for the Eastern District of New York pointed to the chain’s widespread presence, including nearly 300 pharmacies in her district, as an aggravating factor in its alleged misconduct.
The lawsuit highlights the government’s commitment to addressing the opioid crisis and corporate accountability. If Walgreens is found liable, it could face civil penalties of up to $80,850 for each unlawful prescription and treble damages for prescriptions reimbursed by federal programs. Additionally, the court may issue injunctive relief to prevent further violations.
Whistleblowers who worked for Walgreens in different parts of the country brought the allegations to light through the qui tam provisions of the FCA, which allow private parties to sue on behalf of the United States and share in any recovery. Their cases, now consolidated, demonstrate the importance of whistleblower protections in combating health care fraud.
The Justice Department’s complaint reflects its broader strategy to confront the opioid epidemic and hold companies accountable for their role in it. The investigation involved multiple agencies, including the DEA, the Department of Health and Human Services Office of Inspector General, the FBI, and others. Together, these agencies aim to safeguard public health and ensure that pharmacies fulfill their obligations under federal law.
